A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)

NCT06555419 · tracked via the Priya Life Science Germany tracker

Sponsor

Biogen

Phase

Phase 1

Started

2025-01-16

Last updated

2026-09-03

Condition(s) studied

Muscular Atrophy, Spinal

Investigational drug(s) / intervention(s)

Nusinersen →ThecaFlex DRx System

Nusinersen: Administered as specified in the treatment arm.

ThecaFlex DRx System: Implanted as specified in the treatment arm.

Study summary

In this PIERRE-PK study, researchers will learn how the body processes nusinersen when it is given through the ThecaFlex DRx™ System, compared to when nusinersen is given by lumbar puncture (LP). The ThecaFlex DRx system is an investigational implantable medical device developed by Alcyone Therapeutics, Inc. It consists of a catheter, which is a flexible tube, connected to a port which is placed under the skin. Alcyone Therapeutics, Inc. has an ongoing study called PIERRE to test the ThecaFlex DRx system. Participants with spinal muscular atrophy (SMA) in the PIERRE study may be enrolled in the PIERRE-PK study.

The main goal of the PIERRE-PK study is to learn how the body processes nusinersen when given by the ThecaFlex DRx system compared to a lumbar puncture. The main questions researchers want to answer are:

* What is the highest amount of nusinersen found in the blood after dosing?
* How much nusinersen is found in the blood over the first 24 hours after dosing?

The PIERRE-PK study will be done as follows:

* Participants will be screened to check if they can join the study. The screening period will be up to 30 days for this study and may overlap with the PIERRE study.
* Participants will join 1 of 2 groups based on their ongoing nusinersen treatment. One group will be receiving 12 mg doses of nusinersen. The other group will be receiving 28 mg doses of nusinersen.
* Participants will first receive a dose of nusinersen by lumbar puncture.
* The ThecaFlex DRx system will be implanted after the lumbar puncture, as part of the PIERRE study.
* Participants will receive a dose of nusinersen by the ThecaFlex DRx system, as part of the PIERRE study. This dose will be a regular maintenance dose that happens about 4 months after their first dose in this study.
* Researchers will take blood samples before and after each dose. The last blood sample will be taken 24 hours after the dose.
* The total study duration for each participant in the PIERRE-PK study will be approximately 5 months. This period will overlap with the participant's first 5 months in the PIERRE study.

Eligibility

Sex

ALL

Min age

3 Years

Max age

—

Healthy volunteers

Key Inclusion Criteria: \- Participants must be screened in the PIERRE study to be eligible for enrollment in the PIERRE PK study. Participants in the 12 mg group * Participant must have completed all 4 required 12 mg loading doses as per the approved 12 mg dose regimen. * Participant is on regular LP maintenance dosing of nusinersen 12 mg every 4 months, with 120 days ± 14 days between the LP-delivered study dose and the last nusinersen dose prior to study enrollment. Participants in the 28 mg group * Participant must have completed 1 or 2 of the 50 mg loading doses as per the approved 50/28 mg dose regimen. * Participant is on regular LP maintenance dosing of nusinersen 28 mg every 4 months, with 120 days ± 14 days between the LP-delivered study dose and the last nusinersen dose prior to study enrollment. Key Exclusion Criteria: * Ongoing participation or participation within 6 months or 5 half-lives of the agent (whichever is longer) of enrollment in other interventional clinical trials for the treatment of SMA (except for the PIERRE study or interventional clinical trials of myostatin inhibitors \[e.g., apitegromab and taldefgrobep alfa\]). * Participant is naïve to nusinersen treatment. * Participant is receiving nusinersen at a dose other than 12 mg or 28 mg. * Participant has already undergone implantation of the ThecaFlex DRx system or any other implantable medical device for intrathecal (IT) administration. * Participant is pregnant, currently breastfeeding, or intending to become pregnant during the study. NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.

Primary outcome measure(s)

Maximum Observed Concentration (Cmax) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx System — Pre-dose and at multiple time points post-dose over 4 months
Area Under the Plasma Concentration-Time Curve From Zero Time to 24 Hours After Intrathecal Administration (AUC0-24h) of Nusinersen Delivered via Standard LP and via ThecaFlex DRx System — Pre-dose and at multiple time points post-dose over 4 months

Trial sites (21)

Facility	City	Region	Status
St. Joseph's Hospital and Medical Center - Barrow Neurological Institute	Phoenix	Arizona	Recruiting
Children's Hospital of Orange County	Orange	California	Recruiting
Stanford University Medical Center \| Department of Neurology_Palo Alto	Palo Alto	California	Recruiting
Nemours Children's Hospital, Orlando	Orlando	Florida	Recruiting
Ann & Robert H. Lurie Children's Hospital of Chicago	Chicago	Illinois	Recruiting
Boston Children's Hospital	Boston	Massachusetts	Recruiting
Helen DeVos Children's Hospita	Grand Rapids	Michigan	Recruiting
Milton S. Hershey Medical Center \| Pennsylvania State University_Hershey	Hershey	Pennsylvania	Recruiting
Children's Hospital of Philadelphia	Philadelphia	Pennsylvania	Recruiting
Texas Childrens Hospital Houston	Houston	Texas	Recruiting
Stacey Hall Developmental Pediatrics	Charlottesville	Virginia	Recruiting
Children's Hospital of the King's Daughters_Norfolk	Norfolk	Virginia	Recruiting
Hôpital Raymond Poincaré	Garches	Hauts De Seine	Recruiting
Universitaetsklinikum Essen	Essen	Germany	Recruiting
Fondazione Serena Onlus - Centro Clinico Nemo_Milano	Milan	Italy	Withdrawn
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Roma	Italy	Withdrawn
Szpital Specjalistyczny im. L.Rydygiera w Krakowie	Krakow	Poland	Recruiting
Instytut Centrum Zdrowia Matki Polki	Lodz	Poland	Recruiting
Hospital Universitario La Paz	Madrid	Spain	Recruiting
Hospital Universitari i Politecnic La Fe_Valencia	Valencia	Spain	Recruiting
Royal Hallamshire Hospital Neurology Department	Sheffield	South Yorkshire	Recruiting

On this site

📄 Spinraza (nusinersen) drug profile →

More Biogen trials in Germany

A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia Recruiting

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) Recruiting

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation Recruiting

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus Active, not recruiting

A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND) Active, not recruiting

Other trials for the same condition

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy Recruiting

A Study to Learn About the Safety of BIIB115 Injections and How BIIB115 is Processed in the Bodies of Healthy Adult Male Volunteers and of Pediatric Participants With Spinal Muscular Atrophy Who Previously Took Onasemnogene Abeparvovec Active, not recruiting

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06555419 on ClinicalTrials.gov ↗ ← All trials in Germany